Nelarabine Atriance)

Canadian Journal of Health Technologies Pub Date : 2023-10-19 DOI:10.51731/cjht.2023.759

None CADTH

{"title":"Nelarabine Atriance)","authors":"None CADTH","doi":"10.51731/cjht.2023.759","DOIUrl":null,"url":null,"abstract":" CADTH recommends that Atriance should be reimbursed by public drug plans for the treatment of pediatric, adolescent, and young adult patients with intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL) in addition to front-line multiagent chemotherapy if certain conditions are met. Atriance (nelarabine) should only be covered to treat patients with intermediate- and high-risk T-ALL who are aged 1 year to 30 years. Atriance should only be reimbursed as an addition to front-line multiagent chemotherapy. Atriance should be prescribed by clinicians with expertise and experience in treating T-ALL.","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"70 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nelarabine (Atriance)\",\"authors\":\"None CADTH\",\"doi\":\"10.51731/cjht.2023.759\",\"DOIUrl\":null,\"url\":null,\"abstract\":\" CADTH recommends that Atriance should be reimbursed by public drug plans for the treatment of pediatric, adolescent, and young adult patients with intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL) in addition to front-line multiagent chemotherapy if certain conditions are met. Atriance (nelarabine) should only be covered to treat patients with intermediate- and high-risk T-ALL who are aged 1 year to 30 years. Atriance should only be reimbursed as an addition to front-line multiagent chemotherapy. Atriance should be prescribed by clinicians with expertise and experience in treating T-ALL.\",\"PeriodicalId\":9437,\"journal\":{\"name\":\"Canadian Journal of Health Technologies\",\"volume\":\"70 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.51731/cjht.2023.759\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51731/cjht.2023.759","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

& # x0D;CADTH建议，在满足某些条件的情况下，除一线多药化疗外，对于儿童、青少年和年轻成人中高风险t细胞急性淋巴细胞白血病(T-ALL)患者，阿特里安斯应由公共药物计划报销。阿特里安(奈拉滨)只适用于1岁至30岁的中高风险性T-ALL患者。阿特里安斯只能作为一线多药化疗的补充来报销。Atriance应由具有治疗T-ALL专业知识和经验的临床医生开具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Nelarabine (Atriance)

CADTH recommends that Atriance should be reimbursed by public drug plans for the treatment of pediatric, adolescent, and young adult patients with intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL) in addition to front-line multiagent chemotherapy if certain conditions are met. Atriance (nelarabine) should only be covered to treat patients with intermediate- and high-risk T-ALL who are aged 1 year to 30 years. Atriance should only be reimbursed as an addition to front-line multiagent chemotherapy. Atriance should be prescribed by clinicians with expertise and experience in treating T-ALL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Canadian Journal of Health Technologies

自引率

0.00%

发文量